Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients  Martino Introna, Giovanna Lucchini,

Similar presentations


Presentation on theme: "Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients  Martino Introna, Giovanna Lucchini,"— Presentation transcript:

1 Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients  Martino Introna, Giovanna Lucchini, Erica Dander, Stefania Galimberti, Attilio Rovelli, Adriana Balduzzi, Daniela Longoni, Fabio Pavan, Francesca Masciocchi, Alessandra Algarotti, Caterina Micò, Anna Grassi, Sara Deola, Irene Cavattoni, Giuseppe Gaipa, Daniela Belotti, Paolo Perseghin, Matteo Parma, Enrico Pogliani, Josee Golay, Olga Pedrini, Chiara Capelli, Sergio Cortelazzo, Giovanna D’Amico, Andrea Biondi, Alessandro Rambaldi, Ettore Biagi  Biology of Blood and Marrow Transplantation  Volume 20, Issue 3, Pages (March 2014) DOI: /j.bbmt Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Cumulative incidence of GVHD and death post response, for the 27 patients who responded to MSC. The estimates are reported at 1 and 2 years from response assessment with standard errors (se). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Survival and cumulative incidence of death by cause of death for the 40 treated patients. Cumulative incidence of death by cause, for the 40 treated patients, and overall survival by groups. (2A) Shows cumulative incidence of death for the study cohort (40 patients) is represented. Transplantation-related mortality (TRM) and relapse incidence are detailed as specific cause of death. The estimates are reported at 1 and 2 years with standard errors (se). (2B) Shows overall survival from the first MSC administration is presented for the enrolled patients, as specified for GVHD grading at study entry. The estimates are reported at 1 and 2 years with standard errors (se). (2C) Shows overall survival from the first MSC administration is presented for the enrolled patients, as specified for adult and pediatric patients. The estimates are reported at 1 and 2 years with standard errors (se). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions


Download ppt "Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients  Martino Introna, Giovanna Lucchini,"

Similar presentations


Ads by Google